UTILIZATION ANALYSIS

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Somatropin (Genotropin) (0.15 mg/day to 0.3 mg/day): Replacement of Endogenous Growth Hormone in Adults with Growth Hormone Deficiency [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Jan.

Cover of Somatropin (Genotropin) (0.15 mg/day to 0.3 mg/day)

Somatropin (Genotropin) (0.15 mg/day to 0.3 mg/day): Replacement of Endogenous Growth Hormone in Adults with Growth Hormone Deficiency [Internet].

Show details

Contents

< Prev Next >

APPENDIX 1UTILIZATION ANALYSIS

The submitted price for Genotropin ($▬ per milligram) is lower than that of Humatrope ($41.39 per milligram), which is the most widely reimbursed somatropin in Canada (based on public plan data), with an approximate market share of 58% in 2012. A scenario analysis was conducted in which Genotropin was assumed to replace Humatrope. Based on available prevalence data⁵^,⁶ and Canadian population estimates by age and gender for 2012,⁷ this scenario analysis assumed that 78.66% of all units reimbursed for Humatrope were used by adult patients with GHD. This analysis is based on public coverage of Humatrope (no private plans are included). For product costs, both available provincial drug prices and manufacturer-submitted average prices per milligram were used. The results in Table 5 indicate the potential annual cost savings to the drug plan if Genotropin replaced Humatrope.

Table 5

CDR Analysis of Utilization for Genotropin.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK195525

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Somatropin (Genotropin) (0.15 mg/day to 0.3 mg/day): Replacement of Endogenous Growth Hormone in Adults with Growth Hormone Deficiency [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Jan. APPENDIX 1, UTILIZATION ANALYSIS.